Deficit Hyperactivity Disorder / Substance Use Disorder Comorbidity in Integrated Treatment
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris
About this trial
Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders (SUDs) is a highly common comorbid condition associated with serious medical and psychosocial consequences. However, and despite the international consensus recommending integrated treatment for this comorbidity, few studies tested the efficacy of specific psychotherapeutic treatment for this comorbidity.
The aim of this study is to test the efficacy of a specific group Cognitive and Behavioral Therapy (CBT) for the treatment of adults with this comorbidity.
This is a longitudinal, randomized controlled intervention study utilizing a crossover design between the intervention and treatment-as-usual (TAU) waitlist condition, aimed at testing the effectiveness of an integrated psychotherapeutic group treatment for adults with comorbid Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders (SUDs).
Eligibility criteria
Qualifiers
Age 18 or older ;
Suffer from at least one moderate to severe SUD regarding the DSM-5 (tobacco excluded) ;
Being currently treated for a SUD by a physician of a psychologist ;
Being diagnosed with an ADHD according to the DIVA 2.0 of DIVA-5 ;
Disqualifiers
Age under 18;
Pregnant or breastfeeding women;
Not having sign the consent form;
Major difficulties in understanding and/or expressing themselves in french;
Trial design
Treatments tested in this trial
- TAU+integrated group CBT
Treatment groups
132 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov